Bahija Jallal (file photo)
Hot on the heels of a positive PhIII, Immunocore hauls in $175M as it hunts its first TCR OK
Six weeks after Bahija Jallal’s crew at TCR pioneer Immunocore rolled out an upbeat presentation on their lead drug’s interim Phase III data, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
